122 related articles for article (PubMed ID: 36669926)
1. CNS penetration of methotrexate and its metabolite 7-hydroxymethotrexate in mice bearing orthotopic Group 3 medulloblastoma tumors and model-based simulations for children.
Perkins RS; Davis A; Campagne O; Owens TS; Stewart CF
Drug Metab Pharmacokinet; 2023 Feb; 48():100471. PubMed ID: 36669926
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of methotrexate and 7-hydroxymethotrexate and delayed excretion in infants and young children with brain tumors.
Campagne O; Huang J; Lin T; Reddick WE; Selvo NS; Onar-Thomas A; Ward D; Robinson G; Gajjar A; Stewart CF
Eur J Pharm Sci; 2024 Feb; 193():106669. PubMed ID: 38070781
[TBL] [Abstract][Full Text] [Related]
3. CNS Penetration of Cyclophosphamide and Metabolites in Mice Bearing Group 3 Medulloblastoma and Non-Tumor Bearing Mice.
Campagne O; Davis A; Zhong B; Nair S; Haberman V; T Patel Y; Janke L; F Roussel M; Stewart C
J Pharm Pharm Sci; 2019; 22(1):612-629. PubMed ID: 31815662
[TBL] [Abstract][Full Text] [Related]
4. CNS penetration and pharmacodynamics of the CHK1 inhibitor prexasertib in a mouse Group 3 medulloblastoma model.
Campagne O; Davis A; Maharaj AR; Zhong B; Stripay J; Farmer D; Roussel MF; Stewart CF
Eur J Pharm Sci; 2020 Jan; 142():105106. PubMed ID: 31669383
[TBL] [Abstract][Full Text] [Related]
5. Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry.
Guo P; Wang X; Liu L; Belinsky MG; Kruh GD; Gallo JM
J Pharm Biomed Anal; 2007 Apr; 43(5):1789-95. PubMed ID: 17289326
[TBL] [Abstract][Full Text] [Related]
6. CNS penetration of the CDK4/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors.
Patel YT; Davis A; Baker SJ; Campagne O; Stewart CF
Cancer Chemother Pharmacol; 2019 Aug; 84(2):447-452. PubMed ID: 31079218
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of methotrexate in the extracellular fluid of brain C6-glioma after intravenous infusion in rats.
Dukic S; Heurtaux T; Kaltenbach ML; Hoizey G; Lallemand A; Gourdier B; Vistelle R
Pharm Res; 1999 Aug; 16(8):1219-25. PubMed ID: 10468023
[TBL] [Abstract][Full Text] [Related]
8. Influence of C6 and CNS1 brain tumors on methotrexate pharmacokinetics in plasma and brain tissue.
Dukic SF; Kaltenbach ML; Heurtaux T; Hoizey G; Lallemand A; Vistelle R
J Neurooncol; 2004; 67(1-2):131-8. PubMed ID: 15072460
[TBL] [Abstract][Full Text] [Related]
9. In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats.
Devineni D; Klein-Szanto A; Gallo JM
Cancer Chemother Pharmacol; 1996; 38(6):499-507. PubMed ID: 8823490
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Liposomal Formulations on the Release and Brain Delivery of Methotrexate: An In Vivo Microdialysis Study.
Hu Y; Rip J; Gaillard PJ; de Lange ECM; Hammarlund-Udenaes M
J Pharm Sci; 2017 Sep; 106(9):2606-2613. PubMed ID: 28322936
[TBL] [Abstract][Full Text] [Related]
11. Microdialysis-directed Intra-tumor Pharmacokinetic Modeling of Methotrexate in Mice and Humans.
Alsulimani HH; Kim J; Sani SN
J Pharm Pharm Sci; 2016; 19(2):239-51. PubMed ID: 27518173
[TBL] [Abstract][Full Text] [Related]
12. The use of intracerebral microdialysis for the determination of pharmacokinetic profiles of anticancer drugs in tumor-bearing rat brain.
de Lange EC; de Vries JD; Zurcher C; Danhof M; de Boer AG; Breimer DD
Pharm Res; 1995 Dec; 12(12):1924-31. PubMed ID: 8786967
[TBL] [Abstract][Full Text] [Related]
13. PBPK model of methotrexate in cerebrospinal fluid ventricles using a combined microdialysis and MRI acquisition.
Brandhonneur N; Noury F; Bruyère A; Saint-Jalmes H; Le Corre P
Eur J Pharm Biopharm; 2016 Jul; 104():117-30. PubMed ID: 27142258
[TBL] [Abstract][Full Text] [Related]
14. Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study.
Blakeley JO; Olson J; Grossman SA; He X; Weingart J; Supko JG;
J Neurooncol; 2009 Jan; 91(1):51-8. PubMed ID: 18787762
[TBL] [Abstract][Full Text] [Related]
15. The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain.
Sane R; Wu SP; Zhang R; Gallo JM
Drug Metab Dispos; 2014 Apr; 42(4):537-40. PubMed ID: 24464805
[TBL] [Abstract][Full Text] [Related]
16. Influence of schedule of administration on methotrexate penetration in brain tumours.
Dukic SF; Heurtaux T; Kaltenbach ML; Hoizey G; Lallemand A; Vistelle R
Eur J Cancer; 2000 Aug; 36(12):1578-84. PubMed ID: 10930807
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of high-dose methotrexate in Chinese pediatric patients with medulloblastoma.
Shi ZY; Liu YO; Gu HY; Xu XQ; Yan C; Yang XY; Yan D
Biopharm Drug Dispos; 2020 Mar; 41(3):101-110. PubMed ID: 32017134
[TBL] [Abstract][Full Text] [Related]
18. Determination of free extracellular levels of methotrexate by microdialysis in muscle and solid tumor of the rabbit.
Dukic S; Kaltenbach ML; Gourdier B; Marty H; Vistelle R
Pharm Res; 1998 Jan; 15(1):133-8. PubMed ID: 9487560
[TBL] [Abstract][Full Text] [Related]
19. Determination of Methotrexate, 7-Hydroxymethotrexate, and 2,4-Diamino-N
Roberts MS; Selvo NS; Roberts JK; Daryani VM; Owens TS; Harstead KE; Gajjar A; Stewart CF
J Liq Chromatogr Relat Technol; 2016; 39(16):745-751. PubMed ID: 28824272
[TBL] [Abstract][Full Text] [Related]
20. Prolonged methotrexate infusions in children with acute leukemia in relapse and in remission and with medulloblastoma. Pharmacokinetics, toxicity and clinical results.
Janka GE; Mack R; Helmig M; Haas RJ; Bidlingmaier F
Oncology; 1984; 41(4):225-32. PubMed ID: 6589560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
